Opinion
Volume 7:4, 2023

Research and Reports in Medical Sciences

ISSN: 2952-8127 Open Access

Skin Cancer that Originates in Melanocytes

L. Feller*

Department of Periodontology and Oral medicine, Sefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa

Introduction

Skin cancer, particularly melanoma, stands as one of the most formidable challenges in the realm of dermatology and oncology. Melanoma, a type of skin cancer that originates in melanocytes, the cells responsible for skin pigmentation, is notorious for its potential to metastasize and pose a significant threat to overall health. This article delves into the complex world of melanoma, exploring its causes, risk factors, clinical presentation, diagnosis, treatment options, prevention strategies, and the importance of awareness in improving outcomes and promoting early intervention. Melanoma is rooted in the uncontrolled growth of melanocytes, the pigment-producing cells of the skin. A combination of genetic and environmental factors plays a role in its development. Prolonged exposure to UV radiation from the sun or tanning beds is a significant risk factor for melanoma. UV radiation damages DNA in skin cells, potentially triggering cancerous changes. Certain genetic mutations, such as those in the CDKN2A and CDK4 genes, increase the risk of melanoma. A family history of melanoma also raises the likelihood of developing the disease [1].

Description

Individuals with fair skin, light-colored eyes, and red or blonde hair have less natural protection against UV radiation and are more susceptible to melanoma. Having many moles on the body, particularly atypical moles, can increase the risk of melanoma. Melanoma often presents itself as a new or changing mole on the skin. However, not all melanomas follow the same pattern. One half of the mole does not match the other half. The edges of the mole are ragged, blurred, or notched. The mole has different shades of brown, black, or even red, white, or blue. Melanomas are usually larger in diameter than a pencil eraser. A mole that evolves in size, shape, color, or elevation should be examined [2]. Diagnosing melanoma involves clinical evaluation, often coupled with a biopsy for definitive confirmation. Staging the disease determines the extent of its spread, with stages ranging from localized to advanced: The cancer is limited to the outermost layer of skin. The tumor is limited to the skin and is thinner than a certain depth. The tumor has grown thicker but is still localized to the skin. Cancer has spread to nearby lymph nodes. Cancer has spread to distant lymph nodes, organs, or other parts of the body [3].

The choice of treatment depends on factors such as the stage of melanoma, its location, and the patient's overall health. Treatment options include: The tumor and some surrounding tissue are removed. Lymph nodes closest to the tumor are tested to determine if cancer has spread.These drugs stimulate the immune system to target and attack cancer cells. Interleukin-2 (IL-2): A high-dose immunotherapy treatment that stimulates the immune system. These drugs target specific mutations common in melanoma cells. Used for palliative purposes to relieve symptoms when melanoma has spread to other parts of the body. Used in cases where melanoma has spread and cannot be surgically removed. Intravenous (IV) Chemotherapy: Drugs are given through a vein [4].

Preventing melanoma involves a combination of sun protection strategies and early detection. Use broad-spectrum sunscreen with an SPF of 30 or higher and reapply every two hours. Wear long sleeves, wide-brimmed hats, and sunglasses to shield from UV radiation. Stay indoors or seek shade between 10 a.m. and 4 p.m. when the sun is strongest. UV radiation from tanning beds increases the risk of melanoma. Awareness and Early Intervention Raising awareness about melanoma is crucial for early detection and improved outcomes. Advocacy efforts play a vital role in educating communities, funding research, and supporting patients and their families [5].

Conclusion

Melanoma, a formidable adversary in the realm of cancer, demands a comprehensive understanding, proactive prevention strategies, and a united effort to enhance patient outcomes. By delving into the complexities of melanoma's origins, recognizing its symptoms, advocating for early diagnosis, and promoting sun safety, we can pave the way for a world where melanoma is confronted with improved outcomes and a brighter future for those affected. Through collaborative efforts, increased awareness, and ongoing research, the shadows cast by melanoma can be gradually diminished, offering hope and healing to countless individuals and their loved ones.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Farrow, Norma E., Margaret Leddy, Karenia Landa and Georgia M. Beasley. "Injectable therapies for regional melanoma." *Surg Oncol Clin* 29 (2020): 433-444.
2. Tarhini, Ahmad, Christopher Atzinger, Komal Gupte-Singh and Courtney Johnson, et al. "Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA." *J Comp Eff Res* 8 (2019): 461-473.
3. Ghazawi, Feras M., Rami Darwich, Michelle Le, Elham Rahme and Andrei Zubarev, et al. "Uveal melanoma incidence trends in Canada: A national comprehensive population-based study." *Br J Ophthalmol* 103 (2019): 1872-1876.
4. Donley, Grayson M., Wayne T. Liu, Ruth M. Pfeiffer and Emily C. McDonald, et al. "Reproductive factors, exogenous hormone use and incidence of melanoma among women in the United States." *Br J Cancer* 120 (2019): 754-760.
5. Hayek, Sarah A., Amanda Munoz, James T. Dove and Marie Hunsinger, et al. "Hospital-based study of compliance with NCCN guidelines and predictive factors of sentinel lymph node biopsy in the setting of thin melanoma using the national cancer database." *Am Surg* 84 (2018): 672-679.

***Address for Correspondence:** L. Feller, Department of Periodontology and Oral medicine, Sefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa, E-mail: lfeller56@gmail.com*

Received: 01 July, 2023, Manuscript No. rrms-23-112192; **Editor assigned:** 03 July, 2023, PreQC No. P- 112192; **Reviewed:** 15 July, 2023, QC No. Q- 112192; **Revised:** 21 July, 2023, Manuscript No. R- 112192; **Published:** 29 July, 2023, DOI: 10.37421/2952-8127.2023.7.121

How to cite this article: Feller, L. "Skin Cancer that Originates in Melanocytes." *Res Rep Med Sci* 7 (2023): 121.